<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01319734</url>
  </required_header>
  <id_info>
    <org_study_id>22</org_study_id>
    <nct_id>NCT01319734</nct_id>
  </id_info>
  <brief_title>Vitamin C Supplementation Plus Hypoglycemic Agents Versus Hypoglycemic Agents Alone in Type 2 Diabetes Mellitus</brief_title>
  <acronym>Vit C</acronym>
  <official_title>Phase 1 Study of Randomized Clinical Trial Comparing Vitamin C Supplementation Plus Oral Hypoglycemic Drugs Versus Hypoglycemic Drugs Alone on Serum Selenium, Zinc, Copper and Malondialdehyde Levels in Type 2 Diabetes Mellitus and Its Microvascular Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Al-Neelain University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Al-Neelain University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Null hypothesis:

      No significant effect of vitamin C 500 mg Supplementation on the severity of micro-vascular
      complications of type 2 Diabetes Mellitus (DM).

      Alternative hypothesis:

      There is a significant effect of vitamin C 500mg supplementation on the severity of the
      micro-vascular complications of type 2DM.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improving the renal function</measure>
    <time_frame>the renal function will be measure at day 1 and after one month</time_frame>
    <description>vitamin c supplementation act as an antioxidants which reduce the oxidative stress and then can improve the renal function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vitamin C can improve the visual fields</measure>
    <time_frame>the visual field will be assesed at day 1 and after one month</time_frame>
    <description>the damage of the eye can be prevented by decreasing the oxidative stress in the eye, this can be accomplished by vitamin C.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Vitamin C supplementation plus oral hypoglycemic agents arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive vitamin C supplementation 500mg daily for one month and then assessment will done for the patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2DM patients receiving oral hypoglycemic agents alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>this group is the control group who receive oral hypoglycemic agents alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>Vitamin C supplementation 500mg</description>
    <arm_group_label>Vitamin C supplementation plus oral hypoglycemic agents arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glyburide</intervention_name>
    <description>this group receiving glyburide 5 mg alone</description>
    <arm_group_label>Type 2DM patients receiving oral hypoglycemic agents alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of type 2DM

          -  patients in good health

          -  receiving oral hypoglycemic drugs

        Exclusion Criteria:

          -  Insulin dependent diabetes

          -  receiving vitamin complex

          -  smoking

          -  renal disease

          -  liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamdan Z Hamdan, MBBS, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Al-Neelain University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hamdan Z Hamdan, MBBS, Msc</last_name>
    <phone>+249912468264</phone>
    <email>hamdanology@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maha I Mohammed, MBBS, PhD</last_name>
    <phone>+249912230895</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jaber abo aliz</name>
      <address>
        <city>Khartoum</city>
        <zip>1111</zip>
        <country>Sudan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khaled H Bakheet, MD,PhD</last_name>
      <phone>+249912957764</phone>
      <email>khalid2_3456@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Hamdan Z Hamdan, MBBS,MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sudan</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <last_update_submitted>September 17, 2013</last_update_submitted>
  <last_update_submitted_qc>September 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Al-Neelain University</investigator_affiliation>
    <investigator_full_name>Hamdan Zaki Hamdan</investigator_full_name>
    <investigator_title>Al-Neelain University, Faculty of Medicine, Department of Biochemistry and Molecular biology, Khartoum, Sudan</investigator_title>
  </responsible_party>
  <keyword>Vitamin C</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Type 2DM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

